p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells

Cancer Cell

Volumn 29, Issue 6, 2016, Pages 935-948

  Umemura, Atsushi ^a,b   He, Feng ^a   Taniguchi, Koji ^a,f,g   Nakagawa, Hayato ^a,c   Yamachika, Shinichiro ^a   Font Burgada, Joan ^a   Zhong, Zhenyu ^a   Subramaniam, Shankar ^a   Raghunandan, Sindhu ^a   Duran, Angeles ^e   Linares, Juan F ^e   Reina Campos, Miguel ^e   Umemura, Shiori ^a,b   Valasek, Mark A ^a   Seki, Ekihiro ^a,d   Yamaguchi, Kanji ^b   Koike, Kazuhiko ^c   Itoh, Yoshito ^b   Diaz Meco, Maria T ^e   Moscat, Jorge ^e   Karin, Michael ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c San Diego   (Japan)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e BURNHAM INSTITUTE   (United States)

^f KYUSHU UNIVERSITY   (Japan)

^g KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLNITROSAMINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN P62; TRANSCRIPTION FACTOR NRF2; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; MYC PROTEIN; MYC PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; SEQUESTOSOME 1; SQSTM1 PROTEIN, HUMAN; SQSTM1 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIVER; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CANCER STEM CELL; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PATHOLOGY; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DIETHYLNITROSAMINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; NF-E2-RELATED FACTOR 2; PROTO-ONCOGENE PROTEINS C-MYC; SEQUESTOSOME-1 PROTEIN; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84975468197     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.04.006     Document Type: Article

References (67)

1. Chandler, R.J., LaFave, M.C., Varshney, G.K., Trivedi, N.S., Carrillo-Carrasco, N., Senac, J.S., Wu, W., Hoffmann, V., Elkahloun, A.G., Burgess, S.M., et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J. Clin. Invest. 125 (2015), 870–880.
2. Czaja, M.J., Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 140 (2011), 1895–1908.
3. DeNicola, G.M., Chen, P.H., Mullarky, E., Sudderth, J.A., Hu, Z., Wu, D., Tang, H., Xie, Y., Asara, J.M., Huffman, K.E., et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47 (2015), 1475–1481.
4. Denk, H., Stumptner, C., Fuchsbichler, A., Muller, T., Farr, G., Muller, W., Terracciano, L., Zatloukal, K., Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related?. J. Pathol. 208 (2006), 653–661.
5. Duran, A., Amanchy, R., Linares, J.F., Joshi, J., Abu-Baker, S., Porollo, A., Hansen, M., Moscat, J., Diaz-Meco, M.T., p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol. Cell 44 (2011), 134–146.
6. El-Serag, H.B., Hepatocellular carcinoma. N. Engl. J. Med. 365 (2011), 1118–1127.
7. Farber, E., Clonal adaptation during carcinogenesis. Biochem. Pharmacol. 39 (1990), 1837–1846.
8. Finkin, S., Yuan, D., Stein, I., Taniguchi, K., Weber, A., Unger, K., Browning, J.L., Goossens, N., Nakagawa, S., Gunasekaran, G., et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol. 16 (2015), 1235–1244.
9. Font-Burgada, J., Shalapour, S., Ramaswamy, S., Hsueh, B., Rossell, D., Umemura, A., Taniguchi, K., Nakagawa, H., Valasek, M.A., Ye, L., et al. Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. Cell 162 (2015), 766–779.
10. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
11. Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I.B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44 (2012), 694–698.
12. Hay, N., Sonenberg, N., Upstream and downstream of mTOR. Genes Dev. 18 (2004), 1926–1945.
13. Hayes, J.D., McMahon, M., The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol. Cell 21 (2006), 732–734.
14. Hayes, J.D., McMahon, M., NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34 (2009), 176–188.
15. He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S.E., Jepsen, K., et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155 (2013), 384–396.
16. Ichimura, Y., Waguri, S., Sou, Y.S., Kageyama, S., Hasegawa, J., Ishimura, R., Saito, T., Yang, Y., Kouno, T., Fukutomi, T., et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol. Cell 51 (2013), 618–631.
17. Inami, Y., Waguri, S., Sakamoto, A., Kouno, T., Nakada, K., Hino, O., Watanabe, S., Ando, J., Iwadate, M., Yamamoto, M., et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J. Cell Biol. 193 (2011), 275–284.
18. Iwadate, R., Inoue, J., Tsuda, H., Takano, M., Furuya, K., Hirasawa, A., Aoki, D., Inazawa, J., High expression of p62 protein is associated with poor prognosis and aggressive phenotypes in endometrial cancer. Am. J. Pathol. 185 (2015), 2523–2533.
19. Jain, A., Lamark, T., Sjottem, E., Larsen, K.B., Awuh, J.A., Overvatn, A., McMahon, M., Hayes, J.D., Johansen, T., p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J. Biol. Chem. 285 (2010), 22576–22591.
20. Kang, J.S., Wanibuchi, H., Morimura, K., Gonzalez, F.J., Fukushima, S., Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Cancer Res. 67 (2007), 11141–11146.
21. Kaposi-Novak, P., Libbrecht, L., Woo, H.G., Lee, Y.H., Sears, N.C., Coulouarn, C., Conner, E.A., Factor, V.M., Roskams, T., Thorgeirsson, S.S., Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 69 (2009), 2775–2782.
22. Kawai, D., Takaki, A., Nakatsuka, A., Wada, J., Tamaki, N., Yasunaka, T., Koike, K., Tsuzaki, R., Matsumoto, K., Miyake, Y., et al. Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology 56 (2012), 912–921.
23. Kim, Y.R., Oh, J.E., Kim, M.S., Kang, M.R., Park, S.W., Han, J.Y., Eom, H.S., Yoo, N.J., Lee, S.H., Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 220 (2010), 446–451.
24. Kohler, U.A., Kurinna, S., Schwitter, D., Marti, A., Schafer, M., Hellerbrand, C., Speicher, T., Werner, S., Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology 60 (2014), 670–678.
25. Komatsu, M., Waguri, S., Koike, M., Sou, Y.S., Ueno, T., Hara, T., Mizushima, N., Iwata, J., Ezaki, J., Murata, S., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131 (2007), 1149–1163.
26. Komatsu, M., Kageyama, S., Ichimura, Y., p62/SQSTM1/A170: physiology and pathology. Pharmacol. Res. 66 (2012), 457–462.
27. Kuraishy, A., Karin, M., Grivennikov, S.I., Tumor promotion via injury- and death-induced inflammation. Immunity 35 (2011), 467–477.
28. Li, L., Shen, C., Nakamura, E., Ando, K., Signoretti, S., Beroukhim, R., Cowley, G.S., Lizotte, P., Liberzon, E., Bair, S., et al. SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell 24 (2013), 738–750.
29. Linares, J.F., Duran, A., Yajima, T., Pasparakis, M., Moscat, J., Diaz-Meco, M.T., K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells. Mol. Cell 51 (2013), 283–296.
30. Linares, J.F., Duran, A., Reina-Campos, M., Aza-Blanc, P., Campos, A., Moscat, J., Diaz-Meco, M.T., Amino acid activation of mTORC1 by a PB1-domain-driven kinase complex cascade. Cell Rep. 12 (2015), 1339–1352.
31. Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D.F., Chang, Z., Li, J., Peng, B., Fleming, J.B., Wang, H., et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21 (2012), 105–120.
32. Luch, A., Nature and nurture - lessons from chemical carcinogenesis. Nat. Rev. Cancer 5 (2005), 113–125.
33. Maeda, S., Kamata, H., Luo, J.L., Leffert, H., Karin, M., IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005), 977–990.
34. Malhi, H., Kaufman, R.J., Endoplasmic reticulum stress in liver disease. J. Hepatol. 54 (2011), 795–809.
35. Mathew, R., Karp, C.M., Beaudoin, B., Vuong, N., Chen, G., Chen, H.Y., Bray, K., Reddy, A., Bhanot, G., Gelinas, C., et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 137 (2009), 1062–1075.
36. Menon, S., Yecies, J.L., Zhang, H.H., Howell, J.J., Nicholatos, J., Harputlugil, E., Bronson, R.T., Kwiatkowski, D.J., Manning, B.D., Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci. Signal., 5, 2012, ra24.
37. Min, L., Ji, Y., Bakiri, L., Qiu, Z., Cen, J., Chen, X., Chen, L., Scheuch, H., Zheng, H., Qin, L., et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat. Cell Biol. 14 (2012), 1203–1211.
38. Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., Motohashi, H., Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 (2012), 66–79.
39. Mori, H., Inoki, K., Munzberg, H., Opland, D., Faouzi, M., Villanueva, E.C., Ikenoue, T., Kwiatkowski, D., MacDougald, O.A., Myers, M.G. Jr., et al. Critical role for hypothalamic mTOR activity in energy balance. Cell Metab. 9 (2009), 362–374.
40. Muller, T.D., Lee, S.J., Jastroch, M., Kabra, D., Stemmer, K., Aichler, M., Abplanalp, B., Ananthakrishnan, G., Bhardwaj, N., Collins, S., et al. p62 links beta-adrenergic input to mitochondrial function and thermogenesis. J. Clin. Invest. 123 (2013), 469–478.
41. Nakagawa, H., Umemura, A., Taniguchi, K., Font-Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Valasek, M.A., Seki, E., Hidalgo, J., et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26 (2014), 331–343.
42. Nault, J.C., Calderaro, J., Di Tommaso, L., Balabaud, C., Zafrani, E.S., Bioulac-Sage, P., Roncalli, M., Zucman-Rossi, J., Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60 (2014), 1983–1992.
43. Ni, H.M., Woolbright, B.L., Williams, J., Copple, B., Cui, W., Luyendyk, J.P., Jaeschke, H., Ding, W.X., Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J. Hepatol. 61 (2014), 617–625.
44. Ohta, T., Iijima, K., Miyamoto, M., Nakahara, I., Tanaka, H., Ohtsuji, M., Suzuki, T., Kobayashi, A., Yokota, J., Sakiyama, T., et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68 (2008), 1303–1309.
45. Park, E.J., Lee, J.H., Yu, G.Y., He, G., Ali, S.R., Holzer, R.G., Osterreicher, C.H., Takahashi, H., Karin, M., Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140 (2010), 197–208.
46. Qu, A., Jiang, C., Cai, Y., Kim, J.H., Tanaka, N., Ward, J.M., Shah, Y.M., Gonzalez, F.J., Role of Myc in hepatocellular proliferation and hepatocarcinogenesis. J. Hepatol. 60 (2014), 331–338.
47. Rubin, H., Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. Bioessays 33 (2011), 224–231.
48. Sakurai, T., Maeda, S., Chang, L., Karin, M., Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 103 (2006), 10544–10551.
49. Sakurai, T., He, G., Matsuzawa, A., Yu, G.Y., Maeda, S., Hardiman, G., Karin, M., Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14 (2008), 156–165.
50. Sanz, L., Diaz-Meco, M.T., Nakano, H., Moscat, J., The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J. 19 (2000), 1576–1586.
51. Schneider, J.L., Cuervo, A.M., Liver autophagy: much more than just taking out the trash. Nat. Rev. Gastroenterol. Hepatol. 11 (2014), 187–200.
52. Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47 (2015), 505–511.
53. Sell, S., Leffert, H.L., Liver cancer stem cells. J. Clin. Oncol. 26 (2008), 2800–2805.
54. Shibata, T., Aburatani, H., Exploration of liver cancer genomes. Nat. Rev. Gastroenterol. Hepatol. 11 (2014), 340–349.
55. Shibata, T., Ohta, T., Tong, K.I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., Hirohashi, S., Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA 105 (2008), 13568–13573.
56. Solinas, G., Naugler, W., Galimi, F., Lee, M.S., Karin, M., Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc. Natl. Acad. Sci. USA 103 (2006), 16454–16459.
57. Starley, B.Q., Calcagno, C.J., Harrison, S.A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51 (2010), 1820–1832.
58. Suzuki, T., Motohashi, H., Yamamoto, M., Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci. 34 (2013), 340–346.
59. Takamura, A., Komatsu, M., Hara, T., Sakamoto, A., Kishi, C., Waguri, S., Eishi, Y., Hino, O., Tanaka, K., Mizushima, N., Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25 (2011), 795–800.
60. Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., Tsuji, S., Donehower, L.A., Slagle, B.L., Nakamura, H., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46 (2014), 1267–1273.
61. Umemura, A., Park, E.J., Taniguchi, K., Lee, J.H., Shalapour, S., Valasek, M.A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M.N., et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab. 20 (2014), 133–144.
62. Valencia, T., Kim, J.Y., Abu-Baker, S., Moscat-Pardos, J., Ahn, C.S., Reina-Campos, M., Duran, A., Castilla, E.A., Metallo, C.M., Diaz-Meco, M.T., et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 26 (2014), 121–135.
63. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
64. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
65. Wolf, M.J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 26 (2014), 549–564.
66. Zatloukal, K., French, S.W., Stumptner, C., Strnad, P., Harada, M., Toivola, D.M., Cadrin, M., Omary, M.B., From Mallory to Mallory-Denk bodies: what, how and why?. Exp. Cell Res. 313 (2007), 2033–2049.
67. Zavattari, P., Perra, A., Menegon, S., Kowalik, M.A., Petrelli, A., Angioni, M.M., Follenzi, A., Quagliata, L., Ledda-Columbano, G.M., Terracciano, L., et al. Nrf2, but not beta-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology 62 (2015), 851–862.